NonStop Consulting

I am actively recruiting a #Director #RegulatoryAffairs (Global) for a long term client of mine.
 
 This is a role that can be based in: #Switzerland , #Germany , #Austria , Spain, or Poland.
 
 We are seeking someone with extensive global Regulatory experience in the #Biologics or #Biosimilars space. This is the type of role for someone looking to role up their sleeves while also leading end to end strategy.

𝗢𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝗿𝗲 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗶𝗻𝗴 𝗹𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝘀𝗶𝗴𝗻𝗮𝗹𝘀 𝗰𝗼𝗺𝗶𝗻𝗴 𝗼𝘂𝘁 𝗼𝗳 𝗦𝘄𝗶𝘀𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗿𝗲𝗰𝗲𝗻𝘁𝗹𝘆: ANAVEON AG appointing former CureVac CBO Thaminda Ramanayake as CEO. When biotech companies bring in recognised industry leaders like this, it’s usually worth paying attention to what comes next. 𝗪𝗵𝘆? Senior leadership hires in biotech are often strategic signals in themselves, particularly when companies are approaching major inflection points around: → Clinical development → Fundraising → Partnering → Long-term commercial positioning Thaminda is the architect of CureVac’s strategic transformation and its eventual acquisition by BioNTech, Germany’s first all-stock biotech deal, and one of Europe’s most complex transactions involving litigation settlement, royalty sale, and a cross-border multi-jurisdictional structure. Appointments like this often suggest a company is preparing for its next phase of growth - not just scientifically, but commercially and strategically as well. 𝗕𝗶𝗴𝗴𝗲𝗿 𝗽𝗶𝗰𝘁𝘂𝗿𝗲: The Swiss biotech ecosystem continues to mature far beyond early-stage science alone. Basel especially remains one of the most interesting biotech hubs in Europe to watch right now. #Biotech #SwissBiotech #LifeSciences #Biopharma #BiotechLeadership #Basel #HealthcareInnovation #VentureCapital